DREDGECAP
< Home

IMTX

Immatics N.v.
IMTX⚖️CompareForum
⚠️ Verdict
ELEVATED RISK
No dominant structural financial risk is present; the primary risk to existing shareholders is clinical and regulatory execution — the company's value depends entirely on whether its PRAME-directed pipeline candidates (led by anzu-cel and IMA203CD8) achieve regulatory approval, and any clinical setback or FDA rejection would materially impair the company's long-term prospects given zero approved products and ongoing operating losses funded by equity issuance and collaboration payments.
📉
Common Outcome:Financing pressure escalating
⚠️
Secondary Risk:Elevated structural risks
🎯
Confidence:MODERATE
All risk signals are derived directly from SEC filings and supported by cited financial disclosures — not opinion or speculation.

IMTX Stock Risk Analysis

IMTX is a NASDAQ-listed stock with moderate risk characteristics — a DredgeCap risk score of 6.2/10 reflecting a mixed profile that warrants monitoring. The analysis below covers dilution exposure, debt structure, going concern status, and financial position drawn from recent SEC filings. Both risk-relevant disclosures and offsetting strengths are surfaced so shareholders can judge the full picture rather than a single metric.

Company Overview

Immatics N.V. is a Netherlands-incorporated clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, with U.S. operations in Houston, Texas, focused on developing T-cell receptor (TCR)-based immunotherapies targeting PRAME and other intracellular cancer antigens. The company's pipeline includes cell therapy and bispecific modalities, led by anzu-cel (IMA203) and IMA203CD8 in ongoing clinical trials for multiple solid tumor indications. Immatics has not yet received regulatory approval for any product and funds its operations through equity financing and payments from collaboration partners.

AI-generated summary based on SEC filings. May contain errors. See disclosure

Leadership

Harpreet Singh
Harpreet Singh
Chief Executive Officer

Investment Risk Score

NEUTRAL
6.2/10
ELEVATED RISK
Dilution Risk
ELEVATED6.5/10
Liquidity Risk
ELEVATED5.5/10
Debt Toxicity
LOW2.5/10
Profitability Risk
HIGH7.5/10
Premium Report

Full IMTX Stock Risk Report

The integrated analysis — primary risk driver in plain language, expected shareholder outcome, what would materially change the view, and what moves the stock. One-time $7.99, lifetime access for IMTX.

IMTX Risk Summary

⬤
Going Concern
No going concern warning
⬤
Accumulated Deficit
Not present in the provided source material; the 20-F excerpts do not include a balance sheet line item for accumulated deficit as of December 31, 2025.
⬤
Revenue
Declining
⬤
Dilution
134,071,432 ordinary shares were outstanding as of the close of the fiscal year ended December 31, 2025 per the 20-F cover page; the December 2025 equity offering added 12,500,000 ordinary shares, representing an approximately 10.3% increase in share count from that offering alone [Source: 20-F, filed 2026-03-05, Cover Page; 6-K, filed 2025-12-08, offering announcement]. — The company has outstanding warrants listed on NASDAQ under the symbol IMTXW, which represent potential future share issuance; the conversion terms, strike prices, and aggregate warrant count are not present in the provided source material and cannot be quantified from available excerpts.
Conclusion

Immatics is a clinical-stage biotechnology company with no approved products and a pipeline centered on PRAME-directed immunotherapies, a differentiated scientific platform with early clinical evidence of anti-tumor activity in solid tumors. The company reported a €196.4 million net loss for fiscal year 2025 on €48.3 million of collaboration revenue — a sharp year-over-year decline driven by…

What Typically Happens to Stocks Like IMTX

Companies with similar risk profiles — based on dilution exposure, debt structure, revenue trajectory, and going concern status disclosed in SEC filings — frequently experience the patterns below:

📉Material dilution risk from outstanding convertible or variable-price instruments
🔄Possible reverse split or financing restructuring if price weakness continues
📊Value erosion probable unless operating metrics materially improve

These outcomes are based on observed patterns across similar public companies with comparable capital structures — not theoretical projections. The same patterns are commonly observed in OTC-listed companies with similar financing structures and limited revenue generation.

This pattern has repeatedly led to shareholder dilution in similar companies. The question is: How exposed is IMTX specifically?

Premium Report
Unlock the full IMTX report
Plain-English dilution, debt, going-concern, and financials — every claim cited to a filing. One-time $7.99, lifetime access.
Dilution Analysis
Share count history & convertible note terms
View analysis →
Debt Structure
Loan terms, convertible notes & toxic debt
View analysis →
Going Concern
Auditor warnings & viability assessment
View analysis →
Full Financials
Revenue, income, balance sheet trends
View analysis →